Results 31 to 40 of about 28,560 (247)

Metagenomic next-generation sequencing for the diagnosis of Pneumocystis jirovecii Pneumonia in critically pediatric patients

Annals of Clinical Microbiology and Antimicrobials, 2023
Objective The aim of this study was to evaluate the effectiveness of metagenomic next-generation sequencing (mNGS) for the diagnosis of Pneumocystis jirovecii Pneumonia (PCP) in critically pediatric patients.
Hengxin Chen, Yujian Liang, Ruizhi Wang, Yijie Wu, Xiaoyu Zhang, Hao Huang, Xue-gao Yu, Mengzhi Hong, Juhua Yang, K. Liao, Hongxu Xu, Min Liu, Peisong Chen, Yili Chen   +13 more
semanticscholar   +1 more source

Diagnostic value of metagenomic next-generation sequencing of lower respiratory tract specimen for the diagnosis of suspected Pneumocystis jirovecii pneumonia

Annals medicus, 2023
Aim To evaluate diagnostic performance of metagenomic next-generation sequencing (mNGS) for Pneumocystis jirovecii pneumonia (PCP), in comparison with polymerase chain reaction (PCR), Gomori methenamine silver (GMS) staining and serum 1,3-β-d-Glucan (BG)
Yang Liu, Xiaoning Wang, Jun Xu, Qiwen Yang, Huadong Zhu, Jing Yang   +5 more
semanticscholar   +1 more source

Current State of Carbohydrate Recognition and C-Type Lectin Receptors in Pneumocystis Innate Immunity

Frontiers in Immunology, 2021
Pneumocystis jirovecii is one of the most common fungal pathogens in immunocompromised individuals. Pneumocystis jirovecii pneumonia (PJP) causes a significant host immune response that is driven greatly by the organism’s cell wall components including β-
Theodore J. Kottom, Theodore J. Kottom, Eva M. Carmona, Eva M. Carmona, Andrew H. Limper, Andrew H. Limper   +5 more
doaj   +1 more source

Pneumocystis jirovecii pneumonia in patients with decompensated cirrhosis: A Case Series.

International Journal of Infectious Diseases, 2023
OBJECTIVES Pneumocystis jirovecii pneumonia (PCP) incidence is increasing in people without HIV. Decompensated liver cirrhosis is not currently considered as a risk factor for PCP.
E. Franceschini, G. Dolci, Antonella Santoro, M. Meschiari, Alice Ricco, M. Menozzi, G. Burastero, B. Cuffari, N. De Maria, L. Serio, E. Biagioni, B. Catellani, S. Sandro, A. Colecchia, M. Girardis, F. Benedetto, C. Mussini   +16 more
semanticscholar   +1 more source

Not COVID-19, Don’t Overlook Pneumocystis in Patients on Gefitinib!

Current Oncology, 2021
An 82-year-old woman treated for advanced lung cancer with gefitinb was admitted to the emergency unit complaining of dyspnea. Chest computed tomography found abnormalities classified as possible diffuse COVID-19 pneumonia.
Jérémy Barben, Valérie Quipourt, Jérémie Vovelle, Alain Putot, Patrick Manckoundia   +4 more
doaj   +1 more source

Pneumonia por Pneumocystis em 107 Doentes com Infecção por VIH Internados no Serviço de Doenças Infecciosas, Hospital de Santa Maria, Lisboa (2002 - 2013)

Acta Médica Portuguesa, 2016
Introdução: A pneumonia por Pneumocystis jirovecii é das doenças infecciosas oportunistas mais comuns em infectados por vírus da imunodeficiência humana, sendo, actualmente, em Portugal a infecção definidora de sida mais reportada.
Vilma Grilo, Aida Pereira
doaj   +1 more source

Pneumocystis jiroveciipneumonia in developing countries [PDF]

Parasite, 2011
Pneumocystis pneumonia (PcP) is a serious fungal infection among immunocompromised patients. In developed countries, the epidemiology and clinical spectrum of PcP have been clearly defined and well documented. However, in most developing countries, relatively little is known about the prevalence of pneumocystosis.
Yaxsier de Armas Rodríguez, Gustavo Wissmann, André Luis Aquino Müller, Marco Aurélio Pederiva, Maria Carlota Borba Brum, R.L. Brackmann, Virginia Capó de Paz, E. Calderón   +7 more
openaire   +3 more sources

Pneumocystis jirovecii pneumonia associated with immune checkpoint inhibitors: A systematic literature review of published case reports and disproportionality analysis based on the FAERS database

Frontiers in Pharmacology, 2023
Background: Pneumocystis jirovecii pneumonia (PJP) has been reported with ICIs but limited to case reports. The clinical features of PJP with ICIs remain mostly unknown.
Shuang Xia, H. Gong, Yi-kun Wang, Ling Liu, Yichang Zhao, Lin Guo, Bi-kui Zhang, M. Sarangdhar, Y. Noguchi, M. Yan   +9 more
semanticscholar   +1 more source

Epidemiology, Risk Factors, and Prophylaxis Use for Pneumocystis jirovecii Pneumonia in the Non-HIV Population: A Retrospective Study in Québec, Canada

Open Forum Infectious Diseases, 2023
Background Pneumocystis jirovecii pneumonia (PJP) remains a significant threat in immunocompromised cases. Recent data on epidemiology and risk factors for PJP in non-HIV cases are scarce, and guidelines on appropriate prophylaxis are lacking. Methods In
N. Quigley, Laurence d'Amours, P. Gervais, G. Dion   +3 more
semanticscholar   +1 more source

Tension Pneumothorax Following Pneumocystis jirovecii Pneumonia [PDF]

Cureus, 2020
Pneumocystis jirovecii pneumonia (PJP) is one of the most common causes of respiratory failure in patients with human immunodeficiency virus (HIV) infection, for which the mortality rate is approximately 10%. Spontaneous pneumothorax as a presentation of PJP has been reported with rising frequency, but tension pneumothorax as a presentation of PJP is ...
Suwanwongse, Kulachanya, Shabarek, Nehad
openaire   +2 more sources